About Cognoa
Cognoa is a leading pediatric behavioral health company leveraging artificial intelligence (AI) to develop digital diagnostics and therapeutics aimed at improving lifelong outcomes for children at risk for developmental delays. Their core mission is to provide earlier, more accurate, and equitable access to care for behavioral health conditions. The company’s flagship product, Canvas Dx, is the first FDA-authorized diagnosis aid designed to assist physicians in diagnosing autism spectrum disorder (ASD) in children aged 1.5 to 6 years within a primary care setting. This innovative solution utilizes AI to process caregiver-provided information and physician inputs, significantly reducing the diagnostic timeline from months or years to days, thereby enabling earlier intervention during a critical neurodevelopmental window.
By addressing the challenges of specialist shortages and diagnostic disparities, Cognoa’s technology aims to democratize access to timely diagnoses, particularly for underserved populations who often face longer delays. Beyond autism, Cognoa is actively expanding its pipeline of digital diagnostic and therapeutic products to address other significant unmet needs in pediatric behavioral health, including Attention-Deficit/Hyperactivity Disorder (ADHD), Attention Deficit Disorder (ADD), and anxiety in children. The company also offers a child development app to parents, often through employer benefits programs, to support and track their child’s developmental health.
Focus Areas
Business Intelligence
| Key Investors | Morningside Group, Monroe Capital, Stanford Technology Ventures Program, 5Y Capital |
| Partnerships | Wyoming Medicaid, Health Transformation Alliance (HTA), Highmark Insurance, EVERSANA, Autism Learning Partners, LEARN Behavioral |
| Technology | AI-powered digital medicine platform, machine learning algorithms, responsible AI, mobile app-based data collection (videos, questionnaires) |
| FDA Clearances | 1 cleared products (estimated) |
What Physicians Need to Know
For physicians, Cognoa's Canvas Dx offers a streamlined, highly accurate, and efficient tool to diagnose or rule out autism in young children (1.5 to 6 years) directly within primary care settings. This empowers pediatricians to respond to early developmental concerns, reducing the reliance on specialists and shortening the time to diagnosis and intervention. The system provides actionable insights and detailed developmental reports, which can save time on documentation and facilitate better communication with families and educators. Its remote assessment capabilities (parent app for videos and questionnaires) offer a family-friendly experience, and the AI's training on diverse data helps mitigate diagnostic disparities. Cognoa also provides support for documentation and reimbursement, making it practical for clinical integration.
Cognoa's technology, primarily Canvas Dx, integrates seamlessly into the diagnostic workflow through a multi-platform approach. Parents/caregivers utilize a mobile app to complete questionnaires and upload short home videos of their child. Clinicians access a web portal to provide their clinical impressions and review the AI-generated developmental profile and diagnostic prediction. This combination of inputs is processed by Cognoa's machine learning algorithm to deliver a comprehensive assessment.
What the Web Says
Cognoa is a healthcare technology company focused on developing AI-powered digital diagnostics and therapeutics for developmental delays, particularly Autism Spectrum Disorder (ASD). Their primary product, the Cognoa ASD Diagnosis Aid (CanvasDx), is an FDA-authorized software as a medical device intended to assist healthcare providers in diagnosing ASD in young children. Reviews indicate that the product is highly accurate and aims to provide earlier and faster diagnoses, addressing a significant unmet need in pediatric care. While product reviews are generally positive, there is limited public information available regarding company culture or employer reviews on platforms like Glassdoor.
Overall: PositiveStrengths
- Highly accurate AI-powered diagnostic tool for ASD.
- Aims to provide earlier and faster autism diagnoses.
- Reduces dependence on narrow, single-signal tests by combining parent input, clinician input, and objective video analysis.
- FDA-authorized and granted breakthrough designation.
- User-friendly mobile app design for parents and caregivers.
- Potential to scale to other neurodevelopmental and behavioral conditions.
Limitations
- Limited public information on company/employer reviews (e.g., Glassdoor).
- The diagnostic aid is not a stand-alone diagnostic device and requires a healthcare provider's input.
- Risks of misdiagnosis or delayed diagnosis due to false positives or negatives, though these appear to be low.
- Some limitations in customization for certain aspects of their learning and development platform (if considering 'Cognota' as a related entity).
Based on reviews from: G2, Glassdoor, Capterra, Reddit, FDA, Contemporary Pediatrics, Future Human, Whit Grove UX, Indeed.com, PitchBook
Last updated: 2026-07-18
Videos
News, demos, and interviews about Cognoa.
Videos load interactively. If none appear, search YouTube for Cognoa →
Press & Coverage
Frequently Asked Questions
Related Companies
Google DeepMind is a leading artificial intelligence (AI) research laboratory, a subsidiary of Alphabet Inc., dedicated to developing advanced AI systems to benefit humanity. The company focuses on creating general-purpose AI that can learn and solve complex problems, drawing inspiration from neuroscience and machine learning. Their work spans various fields, including healthcare, scientific discovery, and […]
TalkToMedi is a Canadian healthcare AI company that has developed a clinical-grade voice AI platform called MEDI. This platform is designed to automate patient communication and administrative tasks for medical clinics, including family medicine, specialty clinics, allied health, and physiotherapy. MEDI handles high-volume patient calls, automating appointment inquiries, booking, rescheduling, and cancellations based on the […]
Menaela is an AI-first practice management system designed for solo practitioners, small private clinics, and clinic owners. It integrates patient communication, scheduling, CRM, and medical documentation into a single platform, aiming to replace multiple disconnected tools and bots. The system features an AI practice manager that understands natural-language requests, utilizes real clinic data, and performs […]
Avie is operated by AVIE TECNOLOGIA LTDA, headquartered in Santo André, São Paulo, Brazil. Avie provides WhatsApp reception in Brazilian Portuguese, appointment scheduling, rescheduling and cancellations through Google Calendar or Feegow, clinic CRM, follow-up messages and an online booking website. Clinic staff can review conversations and take over when human support is needed. Clinic CRM […]
Saile is a physician-founded healthcare technology company that addresses critical inefficiencies in healthcare staffing and credentialing. Their AI-powered platform acts as a “universal credential passport” for physicians, centralizing and managing all medical licenses, certifications, and CME credits in one secure, portable vault. This system aims to significantly reduce the administrative burden and delays associated with […]
Data Capture Experts (DCE) is an Australian-based healthcare AI company that is at the forefront of digital health transformation. They specialize in developing and implementing digital health platforms that integrate data, technology, and human-centered design to create intuitive and connected healthcare systems. Their flagship platform, DC2Vue, is designed to go beyond traditional Electronic Medical Records […]